FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.

by Sandra Gordon

Reports on breast density inform women of their status but raise questions about what to do next.

by Robin Roenker

A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.

by Sandra Gordon

New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.

by Laura Gesualdi-Gilmore

Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.

by Thomas Celona

Forward Look

Hematologist-oncologist C. Ola Landgren explains how measuring minimal residual disease could be useful in multiple myeloma clinical trials.

by Anna Azvolinsky

From the Editor-in-Chief

A recently approved therapy targets abnormal enzymes produced by gene defects.

by William G. Nelson, MD, PhD

Forward Look

More patients are receiving CAR T-cell therapy for large B-cell lymphoma.

by Leah Lawrence

Forward Look

A new approach that uses a probe to freeze tumor cells followed by an infusion of immune-boosting drugs shows promising results in an early clinical trial.

Forward Look

Targeted therapy extends progression-free survival in people with stage III EGFR-mutated lung cancer.

by Darcy Lewis